
Navigating Stress and Cultivating Wellness During the Holidays
Join NF Northeast on November 19 for a discussion on managing stress, building healthy habits, and cultivating wellness during the holiday season while living with NF1.
NF Northeast is the organization that helps patients through their Journey of Hope.
A diagnosis of NF1, NF2-related schwannomatosis, or schwannomatosis can happen to anyone at any age and at any time.
Our Vision: A world where the burden of neurofibromatosis does not exist.
Our Mission: To bring hope to those affected by neurofibromatosis and allied disorders.
NF Northeast is a highly regarded resource for patients, physicians and scientists. We have provided over $3 million in research grants, and through our advocacy, have been pivotal in generating over $600 million in federally funded NF research. We are known as the “organization with the heart” because ours is a strong and caring community that provides support to newly diagnosed patients and their families.

Join NF Northeast on November 19 for a discussion on managing stress, building healthy habits, and cultivating wellness during the holiday season while living with NF1.

NF patients and their families and friends are invited to join us on the morning of Saturday, November 21st at 9:00 AM for a community-building virtual coffee chat! These chats

Join NF Northeast on December 7 for a discussion on strengthening sibling and family relationships, balancing emotional support, and building meaningful connections while living with NF1.

Looking for a way to support the NF community? Check out the NF Northeast Online Gift Shop, featuring apparel and accessories that help spread awareness of neurofibromatosis (NF). Featured Merchandise

NF Northeast is proud to announce the expansion of our services to the state of Delaware — bringing education, patient advocacy, financial resource guidance, community support, and research funding to

We are incredibly excited to announce that Koselugo (selumetinib) has been FDA‑approved for adults with NF1‑related symptomatic, inoperable plexiform neurofibromas (PN)! Koselugo is an oral MEK inhibitor developed by Alexion,